Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for treating dravet syndrome

A syndrome and subject technology, applied in drug combinations, pharmaceutical formulations, active ingredients of heterocyclic compounds, etc., can solve problems such as insufficient current treatment

Inactive Publication Date: 2020-02-14
CAVION INC
View PDF48 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, current treatments for Dravet syndrome are often inadequate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating dravet syndrome
  • Methods for treating dravet syndrome
  • Methods for treating dravet syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0178] Example 1 Effect of CACNA1G Knockout on Dravet Phenotype

[0179] The Dravet mouse model (see, e.g., Miller et al., Genes Brain Behav. 2014, 13:163-72) was bred to Cav3.1 genetic knockout (KO) mice to generate hybrids of Cacna1g in the Dravet mouse model. KO( figure 1 ). Dravet mice and Cav3.1 KO were tested for spontaneous tonic-clonic seizures and survival. Such as Figure 2A and 2B As shown, in Scn1a + / - Heterozygous deletion of Cacna1g confers a protective benefit on spontaneous generalized tonic-clonic seizures and survival in the Dravet model These data suggest that Cav3.1 may be a useful therapeutic target in the treatment of Dravet syndrome.

Embodiment 2

[0180] Example 2 TTA-A2 to Scn1a + / - Impact of the mouse model

[0181] will be at Scnla + / - TTA-A2, a selective Cav3 antagonist, was evaluated in a mouse model of hyperthermia-induced seizure screening (see eg Miller et al., Genes Brain Behav. 2014, 13: 163-72). Mice will be randomly assigned as treatment or control groups and will be administered TTA-A2 or vehicle by oral gavage. Hyperthermia will be induced until a seizure occurs or maximal temperature is reached, for example, as in image 3 shown. The number of generalized tonic-clonic (GTC) mice was compared between the control and treatment groups. Such as image 3 As shown, "-X" minutes will be determined based on TTA-A2 pharmacokinetics such that maximum brain exposure occurs during seizure induction. The pharmacokinetic data of TTA-A2 are shown in Table 2-3 below. The animal's body temperature will be raised up to 42.5°C and maintained for three minutes or until GTC seizures are observed.

[0182] Table 2

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are methods of treating Dravet syndrome that include administering an effective amount of a T-type calcium channel antagonist to a subject in need of the treatment.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Patent Application Serial No: 62 / 490,357 filed April 26, 2017. The disclosure of this prior application is considered part of (and is incorporated by reference into) the disclosure of the present application. technical field [0003] The present disclosure relates to the treatment of diseases by administering pharmaceutical compounds. In particular, the present disclosure relates to the treatment of Dravet syndrome by administration of T-type calcium channel antagonists. Background technique [0004] T-type calcium channels are low voltage activated calcium channels that open during membrane depolarization and mediate calcium influx into cells following an action potential or depolarizing signal. T-type calcium channels are known to exist in cardiac and smooth muscle, and also in many neuronal cells within the central nervous system. T-type calcium channels (transiently open...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K38/09A61K31/433A61P25/08A61P25/00A61P25/20A61P25/28
CPCA61K38/00A61K45/06A61K31/44A61P25/00A61P25/08A61P25/20A61P25/28A61K33/24A61K31/4412A61K31/00
Inventor 由李·马里切尔埃文·纽博尔德
Owner CAVION INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com